Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Healthcare Review: Sucampo Pharmaceuticals, GlaxoSmithKline, Targacept, DexCom, CEL-SCI, Exelixis Are Movers


Print article Print article
Copyright © Thomson Reuters 2012. All rights reserved.
2012-12-04 00:24:56 -

U.S. stocks barely budged on Monday, with the S&P 500 and Nasdaq trimming early
gains as disappointing U.S. factory numbers dented optimism spurred by positive
data on China's economy. Output by China's factories grew in November for the
first time in more than a year, data showed. But that encouraging signal about
the health of the world's second-largest economy was offset by a surprising
contraction in U.S. manufacturing, which fell in November to its lowest level in
more than three years, according to the Institute for Supply Management.
Following are the notable movers at mid day on Monday:

Sucampo Pharmaceuticals, Inc.(SCMP) shares slumped 7.45% to $4.85 after
announcing Friday the FDA extended by three months its review of the company's
Amitiza drug to treat opioid-induced constipation in patients with chronic, 
non- cancer pain. The FDA decides to extend the goal date to provide time for a full review of supportive analyses it had requested. GlaxoSmithKline plc (GSK) showcases its drugs pipeline to investors and analysts, saying it expects to receive Phase III trial results of up to 14 treatments over the next two years, including for heart medicine darapladib and cancer vaccine MAGE-A3. GSK's strategy is to develop a broader array of drugs, some of which could be blockbusters, although others have smaller commercial potential. Targacept , Inc.(TRGT) shares gained 5.13% to $4.51 on over 167K shares. The stock is still down over 19% so far this year. Targacept, Inc. is a biopharmaceutical company. The Company is engaged in the design, discovery and development of NNR Therapeutics for the treatment of diseases and disorders of the nervous system. The Company's NNR Therapeutics target neuronal nicotinic receptors (NNRs). DexCom, Inc.(DXCM) surged 4.50% to $13.66 with more than 715K shares traded hands - 2X its average volume. DexCom, Inc. (DexCom) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non- diabetic patients. CEL-SCI (AMEX: CVM) continues to climb. Shares were up (3.85%) at mid-day after opening the day even higher. The company issued a shareholder letter stating: "We are encouraged by the study's IDMC findings, and as a result are now more aggressively expanding the study in the US and Western Europe." The biotech is currently running the largest ever Phase III clinical trial in head and neck cancer, a disease with a clear unmet medical need, with their investigational Multikine immunotherapy. Exelixis, Inc.(EXEL) shares slumped 6.15% to $4.58, extending its weekly loss to 13%. Last week, the Food and Drug Administration approved Exelixis, Inc.(NASDAQ:EXEL)'s thyroid cancer drug Cometriq. Cometriq is the first approved drug made by Exelixis. This is also being tested for treatment for prostate cancer, and other types of tumors such as kidney cancer. Content & Media Contact: newseditor@equitybrief.net This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Equity Brief via Thomson Reuters ONE [HUG#1662224]


Press Information:




Contact Person:


Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com